Heterogeneity among lists of cautioned or prohibited drugs in protocols of early-phase oncology trials

Abstract

BACKGROUND: To prevent potential drug-drug interaction, lists of cautioned or prohibited (C/P) drugs are commonly included in protocols of phases I and II cancer trials. Heterogeneity among lists may affect patient eligibility and comparability of results. METHODS: Protocols of phase I/II trials conducted at an academic cancer centre between 2004 and 2009 were reviewed. All C/P drugs were collected and compared among trials.

Authors

You B; Pond G; Siu LL; Nagai J; Cheiken R; Chen E

Journal

Annals of Oncology, Vol. 23, No. 6, pp. 1633–1639

Publisher

Elsevier

Publication Date

June 2012

DOI

10.1093/annonc/mdr476

ISSN

0923-7534

Associated Experts

Gregory Pond

Professor, Faculty of Health Sciences

Visit profile

Labels